INmune Bio Inc (INMB) Major Shareholder Linda F. Powers Buys 61,667 Shares

INmune Bio Inc (NASDAQ:INMB) major shareholder Linda F. Powers acquired 61,667 shares of the company’s stock in a transaction dated Wednesday, May 8th. The stock was acquired at an average price of $9.00 per share, for a total transaction of $555,003.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Shares of INMB traded down $0.07 during mid-day trading on Friday, reaching $10.93. The company’s stock had a trading volume of 6,072 shares, compared to its average volume of 17,566. INmune Bio Inc has a 12-month low of $7.00 and a 12-month high of $11.25.

Separately, Maxim Group initiated coverage on INmune Bio in a report on Tuesday, March 19th. They issued a “buy” rating and a $13.00 price objective on the stock.

WARNING: “INmune Bio Inc (INMB) Major Shareholder Linda F. Powers Buys 61,667 Shares” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at

About INmune Bio

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Featured Article: What does a bar chart display?

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with's FREE daily email newsletter.